HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. - Wikidata - wikimedia - TriplyDB

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

http://www.wikidata.org/entity/Q36132728

about

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge Modeling neutralization kinetics of HIV by broadly neutralizing monoclonal antibodies in genital secretions coating the cervicovaginal mucosa A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike.Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller Boosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylation Challenges in HIV Vaccine Research for Treatment and Prevention.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure.High-throughput Peptide epitope mapping using carbon nanotube field-effect transistors Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01.A mammalian cell based FACS-panning platform for the selection of HIV-1 envelopes for vaccine development Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140 A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.New prospects for a preventive HIV-1 vaccine.Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.Neutralizing antibodies to HIV-1 induced by immunization.

P2860

Q21089588-CFB455BA-FCD3-4D32-A627-92AC40753153 Q27302081-6D850C4F-57A5-4A9B-A764-CA78EB963170 Q27318151-CABFF3B1-29EC-4FF7-A664-46785C1B251D Q27322437-E99F8776-9435-4749-A953-1CB10C5F4CC6 Q27676864-40ED4304-16BC-479C-8FE4-3AD2ECA06FD2 Q27678062-3CEDE28F-E653-42A1-A47E-B50DB8B663A9 Q28263063-D34EB92D-50BB-496D-BF31-36BED19E0476 Q28299280-5C4C6D11-DBE4-4DCD-B3AA-BEC5CB9FB5B3 Q28533970-2EFDD81C-A3D8-4FE3-97A9-38CBD6B2612D Q28534454-FF710E39-1DD3-4478-9068-44F120B5B0C6 Q30490942-7B85AC9B-150A-4561-B656-EB7C5CF4ADE5 Q33620194-1452824F-729E-4242-BA19-FD6A752ECA17 Q33786447-AC2BBEA0-2F25-44D4-882A-DD05CBBB6B1C Q33955745-FD0F6D03-81D4-4190-8685-4BA5E955BEC4 Q34059543-F117D231-B3D9-4641-88DB-E2A0AD551B9F Q34074750-097CF6D9-CCC7-4781-82CF-D36BA13C20FC Q34141693-657F78E9-E000-4B48-A038-1AC9C3F71CDF Q34148683-0563C6F8-5D73-47E3-884F-C2A764B3B565 Q34480254-EEF7ABE4-2669-411F-A021-5B4B10911313 Q34831341-D450CEE0-526F-4786-B07B-53FDFEDE669E Q34955293-2CA69065-A8CE-4FB0-AFF2-24ED25BAE7A3 Q34984724-F199CFBE-EC27-49BA-966A-4E4008159B0F Q35076748-B854CA62-B5C0-430F-BC95-344872EA6A3B Q35092308-C604800C-36E9-44C1-A5EA-D028E1F8BAA7 Q35110976-EDBE9601-AE84-4BA6-A38B-54D8CB087FFC Q35191547-BA97D6F3-93FC-4C3D-A64E-28A10DC563E1 Q35298899-553EA338-22CA-4EF7-8F34-E4E5F4756529 Q35540033-F2CCFE28-F23A-4011-BC82-95333C18ACE3 Q35542610-7B8F1194-89FE-451C-A266-BFE47722A34B Q35580892-190FCE47-EE08-482E-B07C-83F4D26A7001 Q35596474-E9AE2316-5BE3-4CAF-AD1E-FFBC50F28C52 Q35691113-CCDE0506-89B6-4E95-B0FC-6E4FBF7DF437 Q35861256-6F0AE733-8A1E-480B-91D1-26003F626806 Q35883997-6AECE082-E21F-430F-8664-70C63618A05B Q35914280-8C95B956-2926-408E-BFC0-C2E9D0C7B026 Q35925858-C8FB18A8-8595-4CBB-AAFE-4C32C9A46D01 Q36051764-248D89AB-5FD5-4F2C-86DD-90DCDB2613CC Q36223864-80919300-9094-41AA-913F-9574A5233DB0 Q36300153-C545342E-E296-4807-99B5-3AB8FC37C874 Q36603515-A6B59DF8-AD75-404B-8BBB-B4F3A019C8E1

P2860

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

http://www.wikidata.org/entity/Q36132728

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@ast

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@en

type

label

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@ast

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@en

prefLabel

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@ast

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@en

P1433

Q36132728-3AF764FA-78E8-44BE-8665-190AEFC91D4D

P1476

Q36132728-83493142-49E0-457F-944E-CDD19AC1DD10

P2093

Q36132728-2876C216-4755-4B05-B2FE-A1E526EE9221

Q36132728-32751AAC-9416-4510-8C6C-46805A6E5743

Q36132728-39E15EB2-3DB1-405E-A1D0-C5368B5A7036

Q36132728-82D5FF07-2671-49E6-B093-EF843C50CF08

Q36132728-95136F13-E19E-4A68-95A1-5D90D2D9AF69

Q36132728-9EC120C5-1B45-4832-B6B3-0759F2B658F8

Q36132728-A4767C0D-2B95-492A-8E7C-A46E346DFB18

Q36132728-FA0562DF-6A1D-4924-9629-88C35E624258

P2860

Q36132728-00828D2A-AB7D-4312-A114-7CFCA9295F45

Q36132728-07DEDAB6-82BF-4F31-889E-E743E2B8974F

Q36132728-170C9B83-35E3-4252-A42A-3A5720361634

Q36132728-171F0F8E-9165-490B-9429-AA8F9007C52C

Q36132728-1F05C5AD-8E29-4D8E-9538-9A3EF0976EFC

Q36132728-20742FCA-FE82-4BD7-9BBB-AF32C2B7D210

Q36132728-20EEAD16-7D23-46E2-B389-AC9742DE3FD3

Q36132728-213C889B-82E9-4C3A-AA81-18BDA3D6B18C

Q36132728-27629827-269C-4FC1-918A-A6E099334722

Q36132728-2896E253-4A4E-4510-BC57-49570E690A6E

P304

Q36132728-15C83312-7AF8-4F21-922E-03113F78F39F

P31

Q36132728-3AAFC389-3497-4FC1-8B60-046A074A6B7C

P356

Q36132728-070D2BB4-D1C6-4AD3-A8C0-59455951723F

P407

Q36132728-F3B98DE0-9937-4D7D-B183-D095D330CFA1

P433

Q36132728-7F9AD44F-011B-4404-AFD2-2149521A908C

P478

Q36132728-50C72771-4589-497A-B474-D712B1770F80

P50

Q36132728-EDF5BBFC-C471-4683-9B39-D837771CC5EE

P577

Q36132728-9488EEB1-B4E8-4754-9D32-62D5092B367D

P5875

Q36132728-6A59AAFE-24A1-446F-91FA-6BD75E50F80A

P698

Q36132728-E8C2DFD3-7CCD-42EF-9232-8C58F717BAEE

P921

Q36132728-02235D34-9FD5-4892-B3EA-A337A16181FC

P932

Q36132728-BF556888-608B-45CA-BB4B-9599DB9E2991

P356

PNAS.1204533109

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

HIV-1 envelope trimer elicits ...... esponses than monomeric gp120.

@en

P2093

Ann Cheung

http://www.w3.org/2001/XMLSchema#string

Bing Chen

http://www.w3.org/2001/XMLSchema#string

Caroline A Miller

http://www.w3.org/2001/XMLSchema#string

Hanqin Peng

http://www.w3.org/2001/XMLSchema#string

James M Kovacs

http://www.w3.org/2001/XMLSchema#string

James Perry

http://www.w3.org/2001/XMLSchema#string

Joseph P Nkolola

http://www.w3.org/2001/XMLSchema#string

Michael S Seaman

http://www.w3.org/2001/XMLSchema#string

P2860

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

Viral membrane fusion

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

GP120: target for neutralizing HIV-1 antibodies

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

P304

12111-12116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1204533109

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228447294

http://www.w3.org/2001/XMLSchema#string

P698

22773820

http://www.w3.org/2001/XMLSchema#string

P921

P932

3409750

http://www.w3.org/2001/XMLSchema#string